Monday, October 15, 2012

Metabolon vs. Stemina – Are Biomarkers Patents can be Considered as "True Inventions"?

This blog critically analyzes the limitations and pitfalls in biomarker patent process. According to the argument made in this blog, most of the biomarkers patents may not have commercial prospective, though patents are intend to protect the right to manufacture and sell invented products, due to the fact that these biomarkers were identified and characterized without following solid scientific principles and demonstrating clinical applications, which are indispensable for developing commercially viable products. Claimed inventions proposed in patents without adequate scientific research driven supporting evidences and reasonable interpretation of experimental results, as oppose to peer reviewed scientific publications, may not have any scientific value or may not be scientifically acceptable. These patents can also be scientifically mistaken and these patents may not only preclude innovation in biomarker discovery but also hinder the development of low-cost patient care diagnostics products.  Read more: >> Metabolon vs. Stemina – Are Biomarkers Patents can be Considered as “True Inventions”?
Posted by at No comments:

Thursday, October 11, 2012

Neuropsychiatric disease biomarker and drug discovery assays and protocols

Launched an open access database of neuropsychiatric disease biomarker and drug discovery assays and protocols. The listed protocols are extracted from and linked to patents and journal articles. The innovative representation of protocols in this database will be a useful tool for idea/concept generation for developing innovative approaches for neuropsychiatric disease biomarker and drug discovery research. Please follow this link to see the complete list of protocols: Neuropsychiatric disease biomarker and drug discovery assays and protocols
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)